Mother Diagnosed With Cancer Undergoes Chemo, Finds Out She Never Had Cancer After All

Mother Diagnosed With Cancer Undergoes Chemo, Finds Out She Never Had Cancer After All

A member of the dialysis prepares to treat a patient with coronavirus in the intensive care unit at a hospital on May 1, 2020 in Leonardtown, Maryland. The coronavirus death toll in D.C., Virginia and Maryland surpassed 2,000 people on Friday as the District recorded its largest number of daily infections thus far. (Photo by Win McNamee/Getty Images)

OAN’s Abril Elfi
6:12 PM – Tuesday, April 9, 2024

SEE: https://www.oann.com/newsroom/mother-diagnosed-with-cancer-undergoes-chemo-finds-out-she-never-had-cancer-after-all/; republished below in full, unedited, for informational, educational, & research purposes:

A Texas mother says she was diagnosed with cancer and even underwent chemotherapy, only to find out later that she did not have cancer after all.

According to the Daily Mail, 39-year-old Lisa Monk had gone to the hospital in 2022 due to stomach pains that she had suspected were kidney stones. She went through a series of tests during her appointment which showed that she had two kidney stones, as well as a mass on her spleen.

The mother of two then underwent surgery in January 2023 to remove the mass.

According to reports, Monk stated that the spleen had been sent to three different pathology laboratories to be tested before a fourth one found it tested positive for a rare and terminal cancer called “clear cell angiosarcoma.”

The Mayo Clinic states that angiosarcoma is a type of cancer that develops on the lining of lymph and blood vessels. Regardless of age or gender, angiosarcoma is thought to have a poor prognosis despite current treatments.

“It was a blood vessel type of cancer found in the spleen and told me that the most optimistic thing he could say was to give me 15 months [to live],” Monk said. “It was a dark time.” 

Monk then says what followed the diagnosis was an “aggressive” chemotherapy regimen. 

Soon after, she was referred to another hospital and had her first round of chemotherapy in March 2023. After losing all of her hair, Monk explained that she underwent a second round of chemo that left her vomiting and with “silvery skin.”

“It was a very dark time. I was writing goodbye letters and letters to the grandchildren I would never meet and the weddings I would never attend.”

However, Monk said that during a routine appointment in April, a doctor informed her that she never had cancer and that the pathology report “was wrong.”

“I saw the nurse practitioner first and she just asked me about my symptoms and she was scrolling on the computer while she was talking to me,” Monk recalled. “All of a sudden she just stops talking and has this look on her face. She turned to me and looked completely horrified and told me she needed to get the doctor and then ran out of the room. She left me alone for about 15 minutes and the doctor came back in. He said a lot of medical lingo to me and then told me I didn’t have cancer.”

“The doctor then told me that I never had cancer. [At that moment] I looked like I had cancer and I felt like I had cancer as I was vomiting, I was sick and my skin was silvery because of the chemotherapy,” Monk said. 

She continued, stating that the doctor then congratulated her for being cancer-free, rather than apologizing for the huge error.

“The doctor then congratulated me, which really bothered me,” Monk revealed. “At the time I was in shock but now I feel the more appropriate response would be "I'm sorry." I asked for a copy of their pathology report and I found a hallway to call my husband and tell him the news.”

Monk says she only discovered the pathology report was dated a month earlier when she looked at it at home. This means the hospital knew about it before her second round of chemotherapy, but they just did not inform her until the last appointment.

“I had had chemotherapy during this time and they could have told me a month earlier that I would have avoided the second round of chemotherapy if they had bothered to read their own pathology report,” Monk added. “[After being told I didn’t have cancer] I had to wait a couple of days and then it was confirmed to me that it was not cancer after having a discussion with all the doctors. In the end they determined that my spleen was going to rupture which is why it had the mass on it. It was just blood vessel activity and no cancer in it.”

Stay informed! Receive breaking news blasts directly to your inbox for free. Subscribe here. https://www.oann.com/alerts

‘Disturbing’: weedkiller ingredient tied to cancer found in 80% of US urine samples

CDC study finds glyphosate, controversial ingredient found in weedkillers including popular Roundup brand, present in sample

Supported by

More than 80% of urine samples drawn from children and adults in a US health study contained a weedkilling chemical linked to cancer, a finding scientists have called “disturbing” and “concerning”.

The report by a unit of the Centers for Disease Control and Prevention (CDC) found that out of 2,310 urine samples, taken from a group of Americans intended to be representative of the US population, 1,885 were laced with detectable traces of glyphosate. This is the active ingredient in herbicides sold around the world, including the widely used Roundup brand. Almost a third of the participants were children ranging from six to 18.

A bumblebee covered in pollen
Glyphosate weedkiller damages wild bee colonies, study reveals
Read more

Academics and private researchers have been noting high levels of the herbicide glyphosate in analyses of human urine samples for years, but the CDC has only recently started examining the extent of human exposure to glyphosate in the US.

The health impacts of glyphosate are disputed and the CDC report makes no observation about what the detected levels mean in terms of human health outcomes. However, its work comes at a time of mounting concerns and controversy over how pesticides in food and water impact human and environmental health.

“I expect that the realization that most of us have glyphosate in our urine will be disturbing to many people,” said Lianne Sheppard, professor at the University of Washington’s department of environmental and occupational health sciences. Thanks to the new research, “we know that a large fraction of the population has it in urine. Many people will be thinking about whether that includes them.”

Sheppard co-authored a 2019 analysis of people highly exposed to glyphosate, which concluded there was a “compelling link” between glyphosate and an increased risk of non-Hodgkin lymphoma, and also co-authored a 2019 scientific paper that reviewed 19 studies documenting glyphosate in human urine.

Both the amount and prevalence of glyphosate found in human urine has been rising steadily since the 1990s when Monsanto Co. introduced genetically engineered crops designed to be sprayed directly with Roundup, according to research published in 2017 by University of California San Diego School of Medicine researchers.

Paul Mills, the lead researcher of that study, said at the time there was “an urgent need” for a thorough examination of the impact on human health from glyphosate in foods people commonly consume.

More than 200 million pounds of glyphosate are used annually by US farmers on their fields. The weedkiller is sprayed directly over genetically engineered crops such as corn and soybeans, and also over non-genetically engineered crops such as wheat and oats as a desiccant to dry crops out prior to harvest. Many farmers also use it on fields before the growing season, including spinach growers and almond producers. It is considered the most widely used herbicide in history.

Residues of glyphosate have been documented in an array of popular foods made with crops sprayed with glyphosate, including baby food. The primary route of exposure for children is through the diet.

Monsanto and the company that bought it in 2018, Bayer, have maintained that glyphosate and Roundup products are safe, and that residues in food and in human urine are not a health risk.

They are at odds with many researchers and the International Agency for Research on Cancer, a unit of the World Health Organization, which classified glyphosate as a probable human carcinogen in 2015.

The US Environmental Protection Agency (EPA) has taken the opposite stance, classifying glyphosate as not likely to be carcinogenic. But last month a federal appeals court issued an opinion vacating the agency’s safety determination and ordering the agency to give “further consideration” to evidence of glyphosate risks.

“People of all ages should be concerned, but I’m particularly concerned for children,” said Phil Landrigan, who worked for years at the CDC and the EPA and now directs the Program for Global Public Health and the Common Good at Boston College.

“Children are more heavily exposed to pesticides than adults because pound-for-pound they drink more water, eat more food and breathe more air,” Landrigan said. “Also, children have many years of future life when they can develop diseases with long incubation periods such as cancer. This is particularly a concern with the herbicide, glyphosate.”

The new CDC data was released as part of the National Health and Nutrition Examination Survey (NHANES), research that is typically highly valued by scientists.

Cynthia Curl, Boise State University assistant professor of community and environmental health, said it was “obviously concerning” that a large percentage of the US population is exposed to glyphosate, but said it is still unclear how that translates to human health.

 This story is co-published with The New Lede, a journalism project of the Environmental Working Group. Carey Gillam is managing editor of the New Lede and the author of two books addressing glyphosate: Whitewash (2017); and The Monsanto Papers (2021).

 This article was amended on 29 July 2022 to clarify that the 2019 meta-analysis looked for the existence of a link between glyphosate and non-Hodgkin lymphoma by studying the most highly exposed individuals. Reference to the CDC urine analysis drawing no conclusion about health impacts was also added.

The Explosion of Cancer and Latent Disease After COVID Vaccination

Dr. Richard Urso: "From [ages] 25 to 44, we saw last quarter of last year an 82% rise in deaths, so there's a lot of data that's out there that is very, very troubling... This lipid nanoparticle messenger RNA platform, I don't care what you attach it to, it is always going to travel everywhere. It's always going to be a problem. And that's why you see the distribution of disorders coming from this after the vaccines affect so many different organ systems because it distributes everywhere."

Full Video: https://www.theepochtimes.com/part-1-dr-richard-urso-alarming-post-booster-trends-and-the-censorship-of-treatments-for-covid-19_4417659.html

Upload via https://rumble.com/c/Vigilantfox

A normal vaccine stays in the arm, pretty much… 99.9 percent. A lipid nanoparticle needs a door crack to get out. A large majority of the lipid nanoparticle does not stay in the arm. In fact, we now know that a large part of it goes into the lymph node right underneath here and still makes spike protein 60 days later. … That should’ve been looked at well before this product (mRNA COVID-19 shots) was out. They never told people that, hey, we’re going to stick it in your arm… it’s going to show up in your lymph node, it’s going to show up in your brain, it’s going to show up in your ovaries, your bone marrow, your adrenal glands, your liver, your spleen, which is then going to track up through the vagus nerve and go to your basal ganglia.

Is Ivermectin a Cancer Solution?

BY DR. JOSEPH MERCOLA

SEE: https://articles.mercola.com/sites/articles/archive/2022/05/12/ivermectin-antitumor-effects.aspx;

republished below in full unedited for informational, educational & research purposes:

Story at-a-glance

  • Ivermectin has notable antitumor effects, which include inhibiting proliferation, metastasis, and angiogenic activity in cancer cells
  • Ivermectin may target cancer in multiple ways, including inducing apoptosis and autophagy while also inhibiting tumor stem cells and reversing multidrug resistance
  • Along with direct cytotoxic effects, it’s believed that ivermectin regulates the tumor microenvironment, mediating immunogenic cell death
  • The development of an injectable form of ivermectin, or liposomal ivermectin, could help overcome some of its limitations regarding solubility, and open its use to a broader range of cancers
  • Considering that the “war against cancer” has been ongoing for decades, with little to show in terms of lives saved, repurposing existing drugs with favorable safety profiles and notable anticancer effects — like ivermectin — makes sense

Ivermectin is a widely used antiparasitic drug that's listed on the World Health Organization's essential medicines list1 and approved by the U.S. Food and Drug Administration. In low- and middle-income countries, ivermectin is commonly used to treat parasitic diseases including onchocerciasis (river blindness), strongyloidiasis, and other diseases caused by soil-transmitted helminthiasis, or parasitic worms.2

The drug is also used to treat scabies and lice. It's estimated that the total number of ivermectin doses distributed is equal to one-third of the world's population and, as such, "ivermectin at the usual doses (0.2–0.4 mg/kg) is considered extremely safe for use in humans."3

Ivermectin also has demonstrated antiviral and anti-inflammatory properties and made headlines for its potential role in treating COVID-194 — although much of the positive press has been censored and falsely labeled misinformation.5 Now researchers are highlighting another potential use for ivermectin, which is equally as exciting as its potential role in COVID-19 — as an anticancer agent.

Ivermectin's Powerful Antitumor Effects

Ivermectin has notable antitumor effects, which include inhibiting proliferation, metastasis, and angiogenic activity in cancer cells.6 It appears to inhibit tumor cells by regulating multiple signaling pathways, which researchers explained in the Pharmacological Research journal, "suggests that ivermectin may be an anticancer drug with great potential."7

Their graphic, below, shows the multiple ways that ivermectin may target cancer, including inducing apoptosis and autophagy while also inhibiting tumor stem cells and reversing multidrug resistance. They stated that ivermectin "exerts the optimal effect when used in combination with other chemotherapy drugs."8

Many may not be aware that scientists Satoshi ōmura and William C. Campbell won the Nobel Prize in Physiology or Medicine in 2015 for their discovery of ivermectin.9 The medicine is used to treat not only parasitic diseases like malaria but also shows promise for treating asthma and neurological diseases, in addition to cancer.

Along with direct cytotoxic effects, it's believed that ivermectin regulates the tumor microenvironment, mediating immunogenic cell death — another reason for its promise as an anticancer agent.10 Research suggests the drug may be useful for the following cancers:11

Breast cancer — The proliferation of multiple breast cancer cell lines was significantly reduced following treatment with ivermectin.
Digestive system cancer — Ivermectin significantly inhibited the proliferation of gastric cancer cells in vivo and in vitro. The drug also inhibited colorectal cancer cell lines and inhibited the development of hepatocellular carcinoma (liver cancer).
Urinary system cancer — Ivermectin significantly inhibited the proliferation of five renal (kidney) cell carcinoma lines without affecting normal kidney cells. It also had an inhibitory effect on prostate cancer cells.
Hematological cancer — In one study, ivermectin killed leukemia cells at low concentrations while leaving normal hematopoietic cells unharmed.
Reproductive system cancer — Ivermectin inhibited the proliferation of ovarian cancer cell lines and enhanced the efficacy of the conventional chemotherapy drug cisplatin, improving the treatment of epithelial ovarian cancer.
Brain glioma — Ivermectin inhibited the proliferation of human glioblastoma cells in a dose-dependent manner.
Respiratory system cancer — Ivermectin inhibited the development of nasopharyngeal carcinoma in mice, using doses that were not toxic to immune cells known as thymocytes. Ivermectin also significantly inhibited the proliferation of lung cancer cells and may reduce the metastasis of lung cancer cells.
Melanoma — When melanoma cells were treated with ivermectin, their activity was effectively inhibited.

Ivermectin Shows Promise Against Colorectal Cancer

A study published in Frontiers in Pharmacology specifically highlighted ivermectin's potential to fight colorectal cancer, which is the third most common cancer worldwide.12 The drug was found to inhibit colorectal cancer cell growth in a dose-dependent manner as well as promote cell apoptosis.

Further, even at low doses of 2.5 and 5 µM, ivermectin induced cell arrest in colorectal cancer, leading researchers to state, "[I]vermectin might be a new potential anticancer drug therapy for human colorectal cancer and other cancers."13 Considering that the "war against cancer" has been ongoing for decades, with little to show in terms of lives saved, repurposing existing drugs with favorable safety profiles and notable anticancer effects — like ivermectin — makes sense.

The Pharmacological Research scientists similarly noted, "Drug repositioning is a shortcut to accelerate the development of anticancer drugs."14 Not only has ivermectin been shown to permeate tumor tissues effectively, but it has a long history of successful use in humans. They explained that even when doses were increased, no serious adverse effects were found:15

"[T]he broad-spectrum antiparasitic drug IVM (ivermectin), which is widely used in the field of parasitic control, has many advantages that suggest that it is worth developing as a potential new anticancer drug. IVM selectively inhibits the proliferation of tumors at a dose that is not toxic to normal cells and can reverse the MDR [multidrug resistance] of tumors.

Importantly, IVM is an established drug used for the treatment of parasitic diseases such as river blindness and elephantiasis. It has been widely used in humans for many years, and its various pharmacological properties, including long- and short-term toxicological effects and drug metabolism characteristics are very clear. In healthy volunteers, the dose was increased to 2 mg/Kg, and no serious adverse reactions were found …"

Is Liposomal Delivery a Game Changer?

The development of an injectable form of ivermectin, or liposomal ivermectin, could help overcome some of its limitations regarding solubility and open its use to a broader range of cancers. The cancer immunotherapy treatment pembrolizumab, for instance, is approved to treat PD-L1-positive, triple-negative breast cancer, which accounts for only about 20% of cases.

As an immune checkpoint inhibitor, it works best in so-called "hot" tumors, which are already infiltrated by T cells. If ivermectin could be injected into the tumor, inducing T-cell infiltration into the area and inducing immunogenic cancer cell death, it's possible that it could turn a "cold" tumor into a "hot" one, thereby making it more effectively treated.16

Biotech company Mountain Valley MD has developed a liposomal delivery system for ivermectin that they believe could dramatically widen its treatment potential. In an interview with Medical Update Online, Dennis Hancock, Mountain Valley MD president and CEO, explained:17

"So the business value proposition really simply is, we take the best-selling and best-acting drugs and expand their ability to be used on … more types of cancer on a broader spectrum. So you still need the cancer drug and what our Ivectosol does is it enables it to be used in a broader universe …

What's really exciting about the work that Mountain Valley MD is doing is we're enabling drugs that have already been proven in their efficacy and safety to do better and do more faster — so we're not asking people to 'wait five years and see'…"

Most of the research involving ivermectin for cancer to date involves oral or in-vitro administration. Mountain Valley MD is conducting preclinical trials using liposomal ivermectin for metastatic melanoma, non-small cell lung cancer, triple-negative breast cancer and possibly bladder cancers. They also have plans to produce liposomal ivermectin for use in human trials.18 In a news release, Mike Farber, director of life sciences at Mountain Valley MD, stated:19

"The extensive research supporting the drug ivermectin as effective in the inhibition of proliferation, metastasis, and angiogenic activity in a variety of cancers, and as an initiator of immunogenic cell death, is overwhelming. Imagine what is possible when you have the world's only human injectable form of ivermectin that can be directly injected into a tumor or provided through more bio-available forms such as intravenously.

We believe this will be groundbreaking research with near-immediate application to be able to proceed directly to human trials based on the safety and efficacy of ivermectin."

What About Ivermectin for SARS-CoV-2?

In the U.S., ivermectin has been vilified as a treatment for SARS-CoV-2, despite its impressive inhibitory effects on the virus.20 Even the FDA has a dedicated webpage warning "why you should not use ivermectin to prevent COVID-19."21

It's interesting to note, however, that Africa has a lower number of cases, severity of disease, hospitalizations, and deaths than other areas of the world,22 which may be due to using prophylactic medications for endemic infections — ivermectin and others, such as sweet wormwood — that have successfully treated COVID-19.

For instance, a study from Japan demonstrated that just 12 days after doctors were allowed to legally prescribe ivermectin to their COVID-19 patients, the cases dropped dramatically.23 The chairman of the Tokyo Medical Association24 noticed the low number of infections and deaths in Africa, where many use ivermectin prophylactically and as the core strategy to treat river blindness.25 More than 99% of people infected with river blindness live in 31 African countries.

Aside from these observations, a study published in the March 2022 issue of the International Journal of Infectious Diseases found that treatment with ivermectin reduced mortality in COVID-19 patients — and to a greater degree than remdesivir.26

Another recent investigation by Cornell University, posted on the University's preprint server January 20, 2022, found ivermectin outperformed 10 other drugs against COVID-19, making it the most effective against the Omicron variant.27 It even outperformed nirmatrelvir (Paxlovid), which was granted emergency use authorization against COVID-19 in December 2021.

Remdesivir costs between $2,340 and $3,120,28 and nirmatrelvir costs $529 per treatment,29 while ivermectin's average treatment cost is $58.30 Do you think this has anything to do with ivermectin's vilification?

Dr. Pierre Kory, who is part of the group that formed the Front Line COVID-19 Critical Care Working Group (FLCCC) to advance early treatments for COVID-19, pleaded with the U.S. government early on in the pandemic to review the expansive data on ivermectin to prevent COVID-19, and to keep those with early symptoms from progressing and help critically ill patients recover — to no avail.31,32

However, if you'd like to learn more about its potential uses for SARS-CoV-2, FLCCC's I-MASK+ protocol can be downloaded in full,33 giving you step-by-step instructions on how to prevent and treat the early symptoms of COVID-19.

FLCCC also has protocols for at-home prevention and early treatment, called I-MASS, which involves ivermectin, vitamin D3, a multivitamin, and a digital thermometer to watch your body temperature in the prevention phase and ivermectin, melatonin, aspirin, and antiseptic mouthwash for early at-home treatment.

dr mercola covid treatment protocol

Household or close contacts of COVID-19 patients may take ivermectin (18 milligrams, then repeat the dose in 48 hours) for post-exposure prevention.34 Whether ivermectin's potential as an anticancer agent will be stifled the same way it was for COVID-19 remains to be seen, but it appears to be a compound that's worth watching as a potentially powerful agent in the fight against cancer.

50% of Women Had a False-Positive Mammogram After 10 Years

BY DR. JOSEPH MERCOLA

SEE: https://articles.mercola.com/sites/articles/archive/2022/04/12/false-positive-mammogram-results.aspx;

republished below in full unedited for informational, educational & research purposes:

STORY AT-A-GLANCE

  • Data once again show mammograms don't deliver on the promise of effective breast cancer screening as more than half of women in one study had a false positive after 10 years of testing
  • In addition to the added risk from radiation in mammograms that triggers fatal cancer in up to 25 of 100,000 women, the screening does not efficiently identify all cancers, especially in women with dense breasts
  • Women have choices for screening that do not involve radiation, including thermography, ultrasound, and clinical breast examination
  • They can also practice healthy lifestyle choices to reduce risk and maintain optimal levels of omega-3 fatty acid and vitamin D

The effectiveness of consistent early screening mammograms has been studied for many years with mixed results. Current research published by the University of California in March 2022, showed half of all women who got annual mammograms will experience at least one false-positive test after 10 years.1

False-positive testing from mammography as a screening tool can lead to overdiagnosis and overtreatment, including unnecessary biopsies.2 A past study3 from the John Wayne Cancer Institute revealed needle biopsy can increase the spread of cancer compared to patients who received excisional biopsy, also known as lumpectomies.

After a false-positive mammography, needle biopsies are widely used to diagnose breast cancer. But this can accidentally cause malignant cells to spread from the tumor site and encourage metastasis to form in other areas of your body. The researchers from John Wayne Cancer Institute concluded:4

"Manipulation of an intact tumor by FNA [fine-needle aspiration] or large-gauge needle core biopsy is associated with an increase in the incidence of SN [sentinel node] metastases, perhaps due in part to the mechanical disruption of the tumor by the needle."

There's also a significant financial cost to annual mammogram screenings. According to the American Cancer Society,5 73% of women over 45 had a screening mammogram within the past 2 years. In the U.S., these percentages add up to an overwhelming number of women. As of July 1, 2020, there were 62.03 million women from 40 to 70 years in the U.S.6

Assuming the average out-of-pocket cost for a mammogram in the U.S. is roughly $100,7 the total revenue generated is in the billions of dollars. But the financial cost is not the only downside to annual mammogram testing, and women do have other choices for effective screening.

False-Positive Mammograms Are Not Uncommon

The featured study8 was published in JAMA Oncology in March 2022. The researchers asked the question if there was a difference between screening for breast cancer using traditional digital mammography or 3D mammography, also called digital breast tomosynthesis.

Data were collected between January 1, 2005, and December 31, 2018, at 126 facilities. It included 903,495 women aged 40 to 79 years. The results showed there were 2,969,055 nonbaseline screening mammograms interpreted by 699 radiologists; 58% of those mammograms were performed in women younger than 60 years.

Importantly, it was also noted that 46% of these mammograms were on women who had dense breast tissue. Michael Bissell, an epidemiologist in the UC Davis Department of Public Health Sciences and researcher in the study, said in a press release:9

"The screening technology did not have the largest impact on reducing false positives. Findings from our study highlight the importance of patient-provider discussions around personalized health. It is important to consider a patient's preferences and risk factors when deciding on screening interval and modality."

After data collection, the researchers analyzed the type of mammography used, screening interval, age of the woman, and breast density. From this data, they estimated that a woman would have a cumulative risk of at least one false positive after receiving mammograms each year or every other year for 10 years.10

The analysis also showed a false positive resulted in repeated imaging within six months or a biopsy recommendation. The scientists then separated the data for 2D and 3D digital mammography, theorizing that 3D may have a lower risk of a false positive test.

While the theory was proved by the data, the reduction in risk was minimal. They estimated that over 10 years of 3D screening, 50% of women had at least one false-positive test while 56% of those receiving traditional digital mammography had at least one false positive. The comparison between those who had short interval follow-up recommendations and biopsy recommendations differed by only 1%.

Mammograms May Not Work for Women With Dense Breasts

The researchers also found that regardless of whether women had 2D or 3D mammography, the false-positive results were higher in women who had extremely dense breasts.11

The difference between false positives in women who had entirely fatty breasts and those with dense breasts was significant. Using 3D mammography, women with entirely fatty breasts had a 31% probability of a false positive test, while those with dense breasts had a 67.3% probability of a false positive test.12

The researchers also found that, in general, between both types of mammography, women who had almost entirely fatty breasts had a lower probability of a false positive test as compared to women with extremely dense breasts. Additionally, women with dense breasts did not benefit from cancer detection with tomosynthesis.

In addition to the problem with overdiagnosis is the reality that mammograms do not detect all breast cancer. The documentary, “Boobs: The War on Women’s Breasts” available on DVD or Vimeo digital,13 tells the story of Nancy Cappello. Capello was diagnosed with breast cancer after receiving two normal mammograms.

Capello's cancer was missed because she had dense breast tissue. It was only found when her doctor felt the ridge in her breast and prescribed an ultrasound in addition to a mammogram. Capello became a pioneer in the movement to teach women about dense breast tissue and how using a mammogram is "like finding a polar bear in a snowstorm." She said:14

"So I went on a quest — for research — and I discovered for nearly a decade BEFORE my diagnosis, six major studies with over 42,000 women concluded that by supplementing a mammogram with an ultrasound increases detection from 48% to 97% for women with dense tissue.

I also learned that women with extremely dense tissue are 5x more likely to have breast cancer when compared with women with fatty breasts and that research on dense breast tissue as an independent risk factor for breast cancer has been studied since the mid 70s.

… I endured a mastectomy, reconstruction, 8 chemotherapy treatments and 24 radiation treatments. The pathology report confirmed — stage 3c cancer because the cancer had traveled outside of the breast to my lymph nodes. Eighteen lymph nodes were removed and thirteen contained cancer — AND REMEMBER — a "normal" mammogram just weeks before. Is that early detection?"

Cappello succumbed to her breast cancer in 2018 and died after a 15-year fight to beat her cancer,15 but as a result of her efforts, 38 states have passed mandatory breast density reporting laws. The film states that up to 90% of women may have some degree of dense breast tissue that may affect a mammogram's outcome and could benefit from whole breast ultrasound — a procedure that's generally used as an adjunct to a mammogram, rather than a primary test.16

Mammography Radiation Is Not Without Risk

There's also the issue that mammograms use ionizing radiation in a relatively high dose. This, in and of itself, can contribute to the development of breast cancer. A 2016 study concluded:17 "… ionizing radiation as used in low-dose X-ray mammography may be associated with a risk of radiation-induced carcinogenesis."

The researchers pointed out that women who carry a genetic variation or have an inherited disposition of breast cancer should avoid radiation as much as possible. Unfortunately, conventional medicine often recommends routine or even extra mammography for those who have an inherited disposition for breast cancer18 or a genetic mutation.19

The next generation of mammography, 3D tomosynthesis, is basically a CT scan for the breast. Radiation exposure from this is even greater than standard mammograms by a significant margin. According to one study,20 annual screening using digital or film mammography on women aged 40 to 80 years is associated with an induced cancer incidence and fatal breast cancer rate of 20 to 25 cases per 100,000 mammograms.

This means an annual mammogram could cause 20 to 25 cases of fatal cancer for every 100,000 women who got the test. A 3D mammography requires multiple views to get three-dimensionality. It stands to reason your total radiation exposure is considerably higher than from a standard 2D mammogram.

Additionally, data do not support screening asymptomatic women as it is not saving extra lives. A response published in The BMJ21 to research published in The Lancet22 was written by Hazel Thornton, an honorary visiting fellow in the department of health sciences at the University of Leicester. She included reports on her testimony before the House of Commons Health Committee on breast cancer services.

She was asked why she thought the NHS Breast Screening Programme was “a costly trawl of an asymptomatic public group … creating huge costly psychological and physical morbidity,” to which part of her answer was that it:23

“… focuses on the women who benefit, in other words, the one life that is saved, and it overlooks the hundreds of women that go through the process and in some cases suffer psychological harm for that one. It is unbalanced and disproportionate and should be reviewed, in my opinion, at the moment.”

In a Cochrane review of the literature24 they discovered — as Thornton testified — for every 2,000 women screened over 10 years, one avoids dying of breast cancer, and 10 will be treated unnecessarily. Additionally, over 200 women will undergo psychological distress and uncertainty for years after receiving false-positive findings.

One cohort study25 engaged participants in Denmark from 1980 to 2010. They also found screening did not lower the incidence of advanced tumors and concluded: “that 1 in every 3 invasive tumors and cases of DCIS [ductal carcinoma in situ] diagnosed in women offered screening represent overdiagnosis (incidence increase of 48.3%).”26

You Have Choices

Although mammography is the most frequently recommended breast cancer screening tool, you have choices for diagnostic testing that do not involve radiation. Women should be provided enough information to make an informed decision and allowed to use their choice. When you know the options, you can ask to have the test that best suits your situation.

Other potentially safer options for breast examination include clinical breast exams, thermography, and ultrasound. Thermography and ultrasound don't use radiation and can detect abnormalities that mammograms can miss, especially in women with dense breasts.

While it’s also claimed that mammography can catch cancers that an ultrasound misses; according to the National Institutes of Health, “… researchers do not know with full certainty whether 3D mammography is better or worse than standard mammography at avoiding false-positive results and identifying early cancers in all types of patients.”27

Not only that, the U.S. Preventive Services Task Force (USPSTF) on breast cancer screening admits that “… the current evidence is insufficient to assess the benefits and harms of digital breast tomosynthesis (DBT) as a primary screening method for breast cancer.”28

Although they are effective, alternative tests can be difficult to access in the U.S. due to federal guidelines and the influence of the billion-dollar mammography industry. To deny women the use of these screening programs, the USPSTF claims:

“… current evidence is insufficient to assess the balance of benefits and harms of adjunctive screening for breast cancer using breast ultrasonography, magnetic resonance imaging, DBT, or other methods in women identified to have dense breasts on an otherwise negative screening mammogram.”

It's also important to recognize that screening does not prevent breast cancer. Instead, prevention requires healthy lifestyle choices, paying attention to nutritional factors, and avoiding toxins.

For example, vitamin D is of vital nutritional factor that can reduce your risk of all cancer,29 including breast cancer.30 Animal and human studies have also demonstrated that omega-3 fatty acids can help prevent breast cancer and have a positive effect during breast cancer treatment.31

To understand your potential risk, it's crucial that you know your vitamin D level and omega-3 index. Conventional medicine has led many women to believe that simply getting an annual test will protect them from breast cancer. Leading a healthy lifestyle and being informed of your screening options can help you avoid this potentially deadly pitfall.

Cancer patients who recovered but then got “vaccinated” for covid now seeing cancer return with a vengeance

BY ETHAN HUFF

SEE: https://www.naturalnews.com/2022-02-09-cancer-patients-recovered-vaccinated-covid-returns.html; republished below in full for educational & research purposes.

(Natural News) All across the web, reports are emerging about how people who got “fully vaccinated” for the Wuhan coronavirus (Covid-19) are now either sick with new cancer or are suddenly out of remission if they already had cancer previously.

Something inside those chemical vials seems to be triggering the growth of new cancer cells or the reemergence of old ones, these reports suggest. Why else are people’s family members, friends, neighbors or they themselves experiencing a sudden onset of disease?

Ever since Wuhan coronavirus (Covid-19) “vaccines” were first introduced by Donald Trump under Operation Warp Speed, cancer rates have skyrocketed more than threefold, we now know.

“If I had a dollar for every person who has related a story about a friend whose cancer was in remission before the COVID jabs, then became uncontrollable shortly after the jab, I could retire,” writes Steve Kirsch on his Substack blog.

Kirsch spoke with health expert Ryan Cole, whom we previously reported has seen a 20-fold increase in cancers ever since Fauci Flu shots came to be.

How many more people need to get sick and die before these “vaccines” go away for good?

On February 5, Kirsch received two separate emails that he says are representative of the types of comments he receives all the time on his blog. One of them addressed numerous case studies about specific patients who had a massive progression in their cancers post-injection.

The other was from a woman who spoke personally about how two people she knows who got jabbed “now have a cancer that’s pretty serious.”

“I was talking to my doc yesterday and she said one of her patients was diagnosed on Monday and dead by Thursday last week,” this same woman wrote. “[S]he had no previous cancer.”

Another woman named Staci wrote in response to another of Kirsch’s articles that she knows “three people whose cancer was in remission, got the jab and their cancer came back with a vengeance.”

“Two now dead and the third back on systemic chemo,” Staci added. “I fear for my other friends with the BRCA gene.”

Numerous others on Twitter had similar stories to share, including another woman who said that several people she knows who were in remission before getting jabbed now have “an unrelated cancer” post-jab.

“Friend of friend was in remission then after vax developed a sudden cancer in her eye socket that doctors said was very rare,” this person added. “It spread quickly to the bone and blood.”

Another wrote that her grown sibling took all of the mandated injections for work and recently had a “benign neck tumor removed.”

“Not cancerous but no history of it prior either,” this person explained. “I would not be quick to state that jabs which greatly disable main DNA repair not likely to cause new cancers pple otherwise wouldn’t have.”

Another person explained that his mom developed cancer “completely out of the blue” after getting jabbed. From the moment it was discovered it was already stage 4, he says, and “coupled with a massive brain clot and stroke.”

Another wrote that his formerly cancer-free 85-year-old father got injected, and by October of last year had developed a softball-size tumor, which he had to get removed from his abdomen.

By December, the father had stage 4 liver and lung cancer and died about a month later.

“If you’ve recently been vaccinated and your previously under control cancer is now out-of-control, it is highly likely that the cause is that ‘safe and effective’ vaccine you took,” Kirsch says.

More related news about Wuhan coronavirus (Covid-19) “vaccines” can be found at ChemicalViolence.com.

Sources for this article include:

SteveKirsch.substack.com

NaturalNews.com